Figure 1 | Scientific Reports

Figure 1

From: Myostatin inhibition therapy for insulin-deficient type 1 diabetes

Figure 1

MyoLn/Ln animals demonstrate increases in body mass.

MyoLn/Ln diabetic animals do not have the same decreases in body mass typically observed in diabetes. (A) qPCR of skeletal muscle myostatin mRNA expression compared to beta-actin. Two-way ANOVA, **indicates main effect of MyoLn/Ln genotype. p < 0.05; N = 4–7. (B) Body mass changes from 2 to 8 weeks of uncontrolled diabetes. N = 4–16. (C) Body mass at 8 weeks of diabetes. Two-way ANOVA with Bonferroni post-hoc test. *Indicates p < 0.05; N = 5–16.

Back to article page